Loss of RB tumor suppressor staining in pre-treatment breast cancer biopsies can be used prior to initiation of neoadjuvant chemotherapy to predict good tumor response. This association between RB loss and good neoadjuvant response holds regardless of ER status and across various chemotherapy regimens. Assessment of RB status in the pre-treatment biopsy could be useful clinical tool to define patients who are most likely to benefit from neoadjuvant chemotherapy.
Recommended CitationMcFalls, MD, Jeanne; Kline, BA, Jessica; Schwartz, MD, MBA, FACS, Gordon; and Witkiewicz, MD, Angieszka, "Loss of Retinoblastoma (RB) Tumor Suppressor Expression in Breast Cancer Correlates with Better Response to Neoadjuvant Chemotherapy" (2012). Department of Pathology, Anatomy, and Cell Biology Faculty Papers. Paper 82.